Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) was the recipient of unusually large options trading on Wednesday. Stock investors bought 55,757 call options on the company. This is an increase of 112% compared to the typical volume of 26,261 call options.

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors have recently bought and sold shares of the company. Field & Main Bank purchased a new stake in Bristol Myers Squibb in the second quarter worth $527,000. Prosperitas Financial LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $262,000. Archer Investment Corp purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth about $1,399,000. Kingsview Wealth Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $2,598,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $13,408,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on BMY shares. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Wednesday, August 5th. Piper Sandler started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. Citigroup reiterated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Finally, Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Stock Performance

NYSE:BMY traded up $1.06 during trading on Wednesday, reaching $67.11. The company’s stock had a trading volume of 6,624,300 shares, compared to its average volume of 12,254,739. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.64. The firm has a market cap of $137.09 billion, a price-to-earnings ratio of 14.78, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The firm has a 50 day moving average of $59.94 and a 200-day moving average of $59.14. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.